Prescription drug · ANDA
Isotretinoin NDC 70710-1024
Isotretinoin 30 mg/1 · Capsule · Oral · Zydus Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70710-1024-8 | 70710102408 | 3 BLISTER PACK in 1 CARTON (70710-1024-8) / 10 CAPSULE in 1 BLISTER PACKMarketed from Sep 12, 2023 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Isotretinoin
- Generic name (nonproprietary)
- isotretinoin
- Active ingredients
- Isotretinoin — 30 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211568
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 70710-1024_4c0f1aef-5103-4a94-9d2f-5241cd82eeb7SPL ID 4c0f1aef-5103-4a94-9d2f-5241cd82eeb7SPL set ID 28948c32-a598-4bb5-bdb5-efbd87214d98RxCUI 197843, 197844, 197845, 403930UNII EH28UP18IF
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470710102408followed by a unit qualifier and the quantityPackage 70710-1024-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Isotretinoin capsules is indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, isotretinoin capsules is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use : If a second course of isotretinoin capsules treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15-week to 20-week course of treatment [see Dosage and Administratio…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 211568
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Isotretinoin | Isotretinoin 10 mg/1 | CapsuleOral | Zydus Pharmaceuticals USA Inc. | 70710-1022 |
| Isotretinoin | Isotretinoin 10 mg/1 | CapsuleOral | Zydus Lifesciences Limited | 70771-1557 |
| Isotretinoin | Isotretinoin 40 mg/1 | CapsuleOral | Zydus Pharmaceuticals USA Inc. | 70710-1025 |
| Isotretinoin | Isotretinoin 20 mg/1 | CapsuleOral | Zydus Pharmaceuticals USA Inc. | 70710-1023 |
| Isotretinoin | Isotretinoin 20 mg/1 | CapsuleOral | Zydus Lifesciences Limited | 70771-1558 |
| Isotretinoin | Isotretinoin 30 mg/1 | CapsuleOral | Zydus Lifesciences Limited | 70771-1559 |
| Isotretinoin | Isotretinoin 40 mg/1 | CapsuleOral | Zydus Lifesciences Limited | 70771-1560 |